TY - JOUR
T1 - Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
AU - Santoni, Matteo
AU - Heng, Daniel Y
AU - Bracarda, Sergio
AU - Procopio, Giuseppe
AU - Milella, Michele
AU - Porta, Camillo
AU - Matrana, Marc R
AU - Cartenì, Giacomo
AU - Crabb, Simon J
AU - De Giorgi, Ugo
AU - Basso, Umberto
AU - Masini, Cristina
AU - Calabrò, Fabio
AU - Vitale, Maria Giuseppa
AU - Santini, Daniele
AU - Massari, Francesco
AU - Galli, Luca
AU - Fornarini, Giuseppe
AU - Ricotta, Riccardo
AU - Buti, Sebastiano
AU - Zucali, Paolo
AU - Caffo, Orazio
AU - Morelli, Franco
AU - Carrozza, Francesco
AU - Martignetti, Angelo
AU - Gelibter, Alain
AU - Iacovelli, Roberto
AU - Mosca, Alessandra
AU - Atzori, Francesco
AU - Vau, Nuno
AU - Incorvaia, Lorena
AU - Ortega, Cinzia
AU - Scarpelli, Marina
AU - Lopez-Beltran, Antonio
AU - Cheng, Liang
AU - Paolucci, Vittorio
AU - Graham, Jeffrey
AU - Pierce, Erin
AU - Scagliarini, Sarah
AU - Sepe, Pierangela
AU - Verzoni, Elena
AU - Merler, Sara
AU - Rizzo, Mimma
AU - Sorgentoni, Giulia
AU - Conti, Alessandro
AU - Piva, Francesco
AU - Cimadamore, Alessia
AU - Montironi, Rodolfo
AU - Battelli, Nicola
PY - 2019/12/30
Y1 - 2019/12/30
N2 - Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second- or third-line cabozantinib. A multicenter retrospective real-world study was conducted, involving 32 worldwide centers. A total of 237 patients with histologically confirmed clear-cell and non-clear-cell RCC who received cabozantinib as second- or third-line therapy for metastatic disease were included. We analyzed overall survival (OS), progression-free survival (PFS) and time-to-strategy failure (TTSF) using Kaplan-Meier curves. Cox proportional models were used at univariate and multivariate analyses.The median PFS and OS of cabozantinib were 7.76 months (95% CI 6.51-10.88) and 11.57 months (95% CI 10.90-not reached (NR)) as second-line and 11.38 months (95% CI 5.79-NR) and NR (95% CI 11.51-NR) as third-line therapy. The median TTSF and OS were 11.57 and 15.52 months with the sequence of cabozantinib-nivolumab and 25.64 months and NR with nivolumab-cabozantinib, respectively. The difference between these two sequences was statistically significant only in good-risk patients. In the second-line setting, hemoglobin (Hb) levels (HR= 2.39; 95% CI 1.24-4.60, p = 0.009) and IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) group (HR = 1.72, 95% CI 1.04-2.87, p = 0.037) were associated with PFS while ECOG-PS (HR = 2.33; 95%CI, 1.16-4.69, p = 0.018) and Hb levels (HR = 3.12; 95%CI 1.18-8.26, p = 0.023) correlated with OS at multivariate analysis, while in the third-line setting, only Hb levels (HR = 2.72; 95%CI 1.04-7.09, p = 0.042) were associated with OS. Results are limited by the retrospective nature of the study.This real-world study provides evidence on the presence of prognostic factors in RCC patients receiving cabozantinib.
AB - Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second- or third-line cabozantinib. A multicenter retrospective real-world study was conducted, involving 32 worldwide centers. A total of 237 patients with histologically confirmed clear-cell and non-clear-cell RCC who received cabozantinib as second- or third-line therapy for metastatic disease were included. We analyzed overall survival (OS), progression-free survival (PFS) and time-to-strategy failure (TTSF) using Kaplan-Meier curves. Cox proportional models were used at univariate and multivariate analyses.The median PFS and OS of cabozantinib were 7.76 months (95% CI 6.51-10.88) and 11.57 months (95% CI 10.90-not reached (NR)) as second-line and 11.38 months (95% CI 5.79-NR) and NR (95% CI 11.51-NR) as third-line therapy. The median TTSF and OS were 11.57 and 15.52 months with the sequence of cabozantinib-nivolumab and 25.64 months and NR with nivolumab-cabozantinib, respectively. The difference between these two sequences was statistically significant only in good-risk patients. In the second-line setting, hemoglobin (Hb) levels (HR= 2.39; 95% CI 1.24-4.60, p = 0.009) and IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) group (HR = 1.72, 95% CI 1.04-2.87, p = 0.037) were associated with PFS while ECOG-PS (HR = 2.33; 95%CI, 1.16-4.69, p = 0.018) and Hb levels (HR = 3.12; 95%CI 1.18-8.26, p = 0.023) correlated with OS at multivariate analysis, while in the third-line setting, only Hb levels (HR = 2.72; 95%CI 1.04-7.09, p = 0.042) were associated with OS. Results are limited by the retrospective nature of the study.This real-world study provides evidence on the presence of prognostic factors in RCC patients receiving cabozantinib.
U2 - 10.3390/cancers12010084
DO - 10.3390/cancers12010084
M3 - Article
VL - 12
SP - 1
EP - 13
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 1
M1 - E84
ER -